Annual Drug Patent Expiration for BONIVA
Boniva is a drug marketed by Roche and Hoffmann La Roche and is included in two NDAs. It is available from a single supplier. There are three patents protecting this drug and two Paragraph IV challenges.
Drug patent litigation for BONIVA.
This drug has sixty-five patent family members in thirty-two countries.
The generic ingredient in BONIVA is ibandronate sodium. One registered supplier for this compound. Additional details are available on the ibandronate sodium profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
Copyright © DrugPatentWatch. Originally published when a new patent expired for Hoffmann’s drug La BONIVA